Dr. Tyler Curiel is an internationally-recognized expert in innovative treatment of cancer using the body’s own immune system. His training includes a bachelor’s degree from the University of Georgia, a master of public health at Harvard University and his M.D. at Duke University. Dr. Curiel did his residency in internal medicine at Yale University, an infectious disease fellowship at Harvard University and a fellowship in medical oncology at the University of Colorado. He has been the national chair of the American Society of Clinical Oncology Group on experimental therapeutics. He has published extensively on the immune system and cancer, and has been awarded many prestigious grants from the National Institutes of Health for his work.
Christy, B., Demaria, M., Campisi, J., Huang, J., Jones, D., Dodds, S. G., Williams, C., Hubbard, G., Livi, C. B., Gao, X., Weintraub, S., Curiel, T., Sharp, Z. D. & Hasty, P. P53 and Rapamycin are Additive. Oncotarget 6, 15802-15813 (2015). PMID: 26158292; PMCID: PMC4599238
Collins-Burow, B.M., Antoon, J.W., Frigo, D.E., Elliott, S., Weldon, C.B., Boue, S.M., Beckman, B.S., Curiel, T.J., Alam, J., McLachlan, J.A. & Burow, M.E. Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha. J Steroid Biochem Mol Biol. 132(1-2):186-93. doi: 10.1016/j.jsbmb.2012.05.004 (2012). PMID:22634477
Hurez, V., Dao, V., Liu, A., Pandeswara, S., Gelfond, J., Sun, L., Bergman, M., Orihuela, C. J., Galvan, V., Padron, A., Drerup, J., Liu, Y., Hasty, P., Sharp, Z. D. & Curiel, T. J. Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice. Aging Cell. (2015). PMID: 26315673